There are 383 resources available
Other uncommon EGFR mutations: Strategies in management
Presenter: Giulia Pasello
Session: EGFR, Exon 20 and ALK
Resources:
Slides
Webcast
Value of pathological response as an endpoint
Presenter: William Travis
Session: Value of pathological response as an endpoint
Resources:
Slides
Webcast
Introduction
Presenter: Keith Kerr
Session: Value of pathological response as an endpoint
Resources:
Webcast
Live Q&A / discussion
Presenter: Luboš Petruželka, Fabrice Barlesi
Session: Novocure - TTFields: A potential innovative treatment modality in lung cancer
Resources:
Webcast
Introduction
Presenter: Solange Peters
Session: Lung cancer in 2030
Resources:
Webcast
Lung cancer in 2030
Presenter: Pasi Jänne
Session: Lung cancer in 2030
Resources:
Slides
Webcast
Audience Q&A
Presenter: Nicola Normanno
Session: Thermo Fisher Scientific - Enabling future improvements in cancer care with fast next -generation sequencing (NGS) results
Resources:
Webcast
131MO - Trends in age- and sex-specific lung cancer mortality in Europe and Northern America: analysis of vital registration data from the WHO Mortality Database between 2000 and 2017
Presenter: Philip Baum
Session: Mini Oral session 1
Resources:
Abstract
Slides
81MO - Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated Results
Presenter: Chao Lyu
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
108MO - Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
Presenter: Marina Garassino
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast